Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | LPL | P06858 | 2/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26151784 | 0.86 | FFAR1 (0.52) | FFAR1LPLLIPG | |
| SCHEMBL1559915 | 0.86 | FFAR1 (0.57) | FFAR1LPLLIPG | |
| SCHEMBL18985789 | 0.85 | FFAR1 (0.53) | FFAR1LPLLIPG | |
| SCHEMBL31753610 | 0.84 | FFAR1 (0.52) | FFAR1LPLLIPG | |
| SCHEMBL2997065 | 0.83 | FFAR1 (0.55) | FFAR1LPLLIPG | |
| SCHEMBL2515840 | 0.83 | FFAR1 (0.55) | FFAR1LPLLIPG | |
| SCHEMBL16968061 | 0.83 | FFAR1 (0.55) | FFAR1LPLLIPG | |
| SCHEMBL28507860 | 0.82 | FFAR1 (0.53) | FFAR1LPLLIPG | |
| SCHEMBL14858165 | 0.82 | FFAR1 (0.53) | FFAR1LPLLIPG | |
| SCHEMBL18985768 | 0.82 | FFAR1 (0.56) | FFAR1LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | AMGEN INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-12448396-B2 | Methods of using heterocyclic compounds as Delta-5 Desaturase inhibitors | AMGEN INC. (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2024253416-A1 | PYRIMIDINE/PYRIDINE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2024-12-12 | — | — | WO | disclosed |
| CN-118161500-A | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | 安进公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-114728167-B | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | 安进公司 | 2024-03-19 | — | — | CN | disclosed |
| EP-3644991-B1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME LLC (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230159560-A1 | METHODS OF USING HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS | APTUIT (VERONA) SRL, AN EVOTEC COMPANY (IT) | 2023-05-25 | — | — | US | disclosed |
| US-20230159560-A1 | METHODS OF USING HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS | APTUIT (VERONA) SRL, AN EVOTEC COMPANY (IT) | 2023-05-25 | — | — | US | disclosed |
| US-20230159560-A1 | METHODS OF USING HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS | APTUIT (VERONA) SRL, AN EVOTEC COMPANY (IT) | 2023-05-25 | — | — | US | disclosed |
| US-11512097-B2 | Heterocyclic compounds as Delta-5 desaturase inhibitors and methods of use | AMGEN INC. (US) | 2022-11-29 | — | — | US | disclosed |
| US-20210171529-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2021-06-10 | — | — | US | disclosed |
| WO-2021108408-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021108408-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021108404-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-19 | — | — | US | disclosed |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-19 | — | — | US | disclosed |
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-14 | — | — | US | disclosed |
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-14 | — | — | US | disclosed |
| WO-2019005588-A1 | 3-(1H-PYRAZOL-4-YL)PYRIDINE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2019-01-03 | — | — | WO | disclosed |
| WO-2017102091-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11512097-B2 | Heterocyclic compounds as Delta-5 desaturase inhibitors and methods of use | SCD5, SCD, FADS2 | FFAR1 456/4885LPL 149/4885LIPG 217/4885 |
| US-12448396-B2 | Methods of using heterocyclic compounds as Delta-5 Desaturase inhibitors | SCD5, SCD, FADS2 | FFAR1 490/4885LPL 94/4885LIPG 153/4885 |
| US-20230159560-A1 | METHODS OF USING HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS | SCD5, SCD, FADS2 | FFAR1 490/4885LPL 94/4885LIPG 153/4885 |
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | CCNI, CCNT2, CDK2 | FFAR1 3190/4885LPL 3470/4885LIPG 2413/4885 |
| US-20210171529-A1 | HETEROCYCLIC COMPOUNDS AS DELTA-5 DESATURASE INHIBITORS AND METHODS OF USE | SCD5, SCD, FADS2 | FFAR1 448/4885LPL 152/4885LIPG 205/4885 |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | CCNI, CCNT2, CDK2 | FFAR1 3190/4885LPL 3470/4885LIPG 2413/4885 |
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | SCD5, SCD, FADS2 | FFAR1 448/4885LPL 152/4885LIPG 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.